- Home
- JCI vs ZTS Comparison
JCI vs ZTS Comparison
Compare JCI & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCI
- ZTS
- Stock Information
- Founded
- JCI 1885
- ZTS 1952
- Country
- JCI Ireland
- ZTS United States
- Employees
- JCI N/A
- ZTS N/A
- Industry
- JCI Industrial Machinery/Components
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- JCI Industrials
- ZTS Health Care
- Exchange
- JCI Nasdaq
- ZTS Nasdaq
- Market Cap
- JCI 67.9B
- ZTS 66.3B
- IPO Year
- JCI N/A
- ZTS 2013
- Fundamental
- Price
- JCI $106.49
- ZTS $147.40
- Analyst Decision
- JCI Buy
- ZTS Buy
- Analyst Count
- JCI 15
- ZTS 8
- Target Price
- JCI $107.79
- ZTS $204.00
- AVG Volume (30 Days)
- JCI 5.0M
- ZTS 3.3M
- Earning Date
- JCI 07-29-2025
- ZTS 08-05-2025
- Dividend Yield
- JCI 1.39%
- ZTS 1.36%
- EPS Growth
- JCI 41.38
- ZTS 7.32
- EPS
- JCI 3.37
- ZTS 5.57
- Revenue
- JCI $23,402,000,000.00
- ZTS $9,286,000,000.00
- Revenue This Year
- JCI $3.45
- ZTS $3.63
- Revenue Next Year
- JCI $4.98
- ZTS $6.13
- P/E Ratio
- JCI $35.44
- ZTS $26.46
- Revenue Growth
- JCI 14.26
- ZTS 6.32
- 52 Week Low
- JCI $64.31
- ZTS $139.70
- 52 Week High
- JCI $112.63
- ZTS $200.33
- Technical
- Relative Strength Index (RSI)
- JCI 50.99
- ZTS 36.45
- Support Level
- JCI $102.09
- ZTS $148.54
- Resistance Level
- JCI $112.63
- ZTS $152.30
- Average True Range (ATR)
- JCI 2.46
- ZTS 2.92
- MACD
- JCI -0.67
- ZTS -0.26
- Stochastic Oscillator
- JCI 41.75
- ZTS 19.97
About JCI Johnson Controls International plc
Johnson Controls manufactures, installs, and services commercial HVAC systems, building management platforms and controls, fire and security solutions, and industrial refrigeration units. Commercial HVAC and fire and security each account for approximately 45% of sales, while industrial refrigeration and other solutions account for the remaining 10% of revenue. In fiscal 2024, Johnson Controls generated nearly $23 billion in pro forma revenue.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.